New vaccine approach triggers neutralizing antibody production and T-cell responses and lowers risk of infection.

Molnupiravir, the first oral antiviral for COVID-19, reduces the risk of hospitalization or death if started within five days.

HCV treatment initiation dropped by 31% from March to April 2020 and remained low throughout the year.

Molnupiravir reduces severe illness and death, but it must be started within days after developing symptoms.

COVID-19 vaccines are highly effective, but people with a low CD4 count or detectable viral load are at risk for poor response.

Boosters further reduce the risk of severe illness and can help curb coronavirus transmission.

Paxlovid dramatically reduced the risk of severe illness and death, but it must be started soon after developing symptoms.

The number of people treated for hepatitis C hit a low point during the COVID-19 pandemic.

Inner ear infection could explain hearing and balance issues in some people with COVID-19.

Post-exposure and pre-exposure prophylaxis could be a game-changer for immunocompromised people.